Meiotic abnormalities of the allotriploid <i>P</i>. <i>alba</i> × <i>P</i>. <i>berolinensis</i> ‘Yinzhong’.

<p>a. Early metaphase I with several univalents and trivalents (arrows); b–c. Metaphase I with a multipolar spindle showing chromosome arrangement (b) and microtubule distribution (c); d. Metaphase I with precociously migrated chromosomes; e. Anaphase I with lagging chromosomes (arrow); f. Telophase I with micronucleus (arrow); g. Telophase II with micronucleus (arrow); h. Anaphase II with chromosome bridge (arrow); i. DAPI stained Telophase II showing chromosome bridge (arrow). a, d–h Bars are equal to 10 μm; b, c, i Bars are equal to 5 μm.</p

Precocious cytokinesis and nuclear fusion.

<p>a–d. Precocious cytokinesis in prophase II (a), metaphase II (b), anaphase II (c) and telophase II (d); e. Completion of successive cytokinesis showing formation of secondary cell plates between sister nuclei (arrows); f. Telophase II with precocious cytokinesis showing a fused nucleus in a daughter cell and separate nuclei by phragmoplast (arrow) in the other cell; g. Telophase II with precocious cytokinesis showing nuclear fusion in both daughter cells; h. Triad with a fused nucleus; i. Dyad with two fused nuclei. Bars are equal to 10 μm.</p

Meiotic pairing configuration of the allotriploid <i>P</i>. <i>alba</i> × <i>P</i>. <i>berolinensis</i> ‘Yinzhong’.

<p>Meiotic pairing configuration of the allotriploid <i>P</i>. <i>alba</i> × <i>P</i>. <i>berolinensis</i> ‘Yinzhong’.</p

Segregation of ploidy levels in the progeny between <i>P</i>. <i>tomentosa</i> × <i>P</i>. <i>bolleana</i> YB03 and <i>P</i>. <i>alba</i> × <i>P</i>. <i>berolinensis</i> ‘Yinzhong’.

<p>a. Histogram of seedling number with different ploidy levels among the progeny (Aneuploid I: containing chromosome number between 38 and 57; Aneuploid II: containing chromosome number between 57 and 76); b–e. Somatic chromosome counting in some aneuploid individuals. The chromosome numbers are 45 (b), 52 (c), 53 (d), and 68 (e).</p

Spindle misorientations and meiotic products.

<p>a–c. Anaphase II with parallel spindles (a), fused spindles (b) and tripolar spindles (c); d. Metaphase II with an organelle band (arrow) between two spindles; e–f. Metaphase II with a mini-spindle showing chromosome arrangement (e) and microtubule distribution (f); g–h. Anaphase II with a mini-spindle showing chromosome arrangement (g) and microtubule distribution (h); i. Polyad with microcytes (arrow); j–o. Tetrads with different arrangements of daughter cells; p. Tetrad with unbalanced cytokinesis. Bars are equal to 10 μm in (a)–(c), (i)–(p); bars are equal to 5 μm in (d)–(h).</p

Somatic chromosome counting (2n = 3x = 57) of <i>P</i>. <i>alba</i> × <i>P</i>. <i>berolinensis</i> ‘Yinzhong’.

<p>Arrows indicate the chromosome I. Bar is equal to 10 μm.</p

Pollen grains of <i>P</i>. <i>alba</i> ×<i>P</i>. <i>berolinensis</i> ‘Yinzhong’ and their germination.

<p>a. Pollen morphology of ‘Yinzhong’; b. Histogram of frequency distribution of pollen diameter; c. Pollen germination <i>in vitro</i>.</p

Additional file 1 of Long non-coding RNA CASC7 is a promising serum biomarker for hepatocellular carcinoma

Supplementary Material

Serum APE1 Autoantibodies: A Novel Potential Tumor Marker and Predictor of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer

<div><p>Apurinic/apyrimidinic endonuclease 1 (APE1), which has the dual functions of both DNA repair and redox activity, has been reported to be highly expressed in non-small cell lung cancer (NSCLC), and this appears to be a characteristic related to chemotherapy resistance. In this study, we identified serum APE1 autoantibodies (APE1-AAbs) in NSCLC patients and healthy controls by immunoblotting and investigated the expression of APE1-AAbs by indirect ELISA from the serum of 292 NSCLC patients and 300 healthy controls. In addition, serum APE1-AAbs level alterations of 91 patients were monitored before and after chemotherapy. Our results showed that serum APE1-AAbs can be detected in both NSCLC patients and healthy controls. Serum APE1-AAbs were significantly higher than those of healthy controls and closely related to APE1 antigen levels both in tumor tissues and the peripheral blood. Moreover, the change in levels of serum APE1-AAbs in NSCLC is closely associated with the response to chemotherapy. These results suggest that APE1-AAbs is a potential tumor marker and predictor of therapeutic efficacy in NSCLC.</p> </div

Characteristics and serum APE1-AAbs distribution of NSCLC patients with pre- and post- chemotherapy.

<p><i>p</i> value were obtained after comparing the levels APE1-AAbs of pre- and post- chemotherapy, as determined by paired <i>t</i>-test.</p